FTSE MIB
33.629,21 -107,19 (-0,32%) Dow Jones
38.675,68 +450,02 (+1,18%) Nasdaq
16.156,33 +315,37 (+1,99%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
77,99 -0,96 (-1,22%) Bitcoin EUR
58.598,74 +3.583,31 (+6,51%)
AC Immune SA (ACIU)
Dopo ore:
| Chiusura precedente | 2,4400 |
| Aperto | 2,4300 |
| Denaro | 2,3500 x 100 |
| Lettera | 2,4200 x 100 |
| Min-Max giorno | 2,3700 - 2,4500 |
| Intervallo di 52 settimane | 1,9000 - 5,1400 |
| Volume | |
| Media Volume | 181.077 |
| Capitalizzazione | 236,368M |
| Beta (5 anni mensile) | 1,01 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,7000 |
| Prossima data utili | 02 ago 2024 - 06 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 10,49 |
GlobeNewswireAC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023
AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023 Lausanne, Switzerland, October 5, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will present a corporate overview and participate in one-on-one investor meetings during the Jefferies 2023 CNS & Neuro Summit, taking place in-person in New York City on October 11-12, 2023. AC Immune’s cor
- GlobeNewswire
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023 Lausanne, Switzerland, September 05, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company will present a corporate overview and participate in one-on-one investor meetings during the H.C. Wainwright 25th Annual Global Investment Conference, taking place virtually and in-perso
- GlobeNewswire
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update Received FDA Fast Track Designation for ACI-24.060 anti-amyloid-beta (Abeta) active immunotherapy to treat Alzheimer’s disease (AD)Enrollment in ongoing Phase 1b/2 ABATE study of ACI-24.060 in AD and Down syndrome (DS) is on track and expanding to sites in USA following IND clearance, dosed first individual with DSNext interim safety and immunogenicity data from AD and DS cohorts in ABATE expected in H2 2023R
